Medicine
Dopram 400 mg/20 mL injection
Dopram 400 mg/20 mL injection is a prescription medicine containing Doxapram for intravenous use, marketed by Hikma Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at Controlled Room Temperature, Between 20˚C to 25˚C (68˚F to 77˚F).
Key facts
- Active ingredient (INN)
- Doxapram
- Brand
- Dopram
- Strength
- 400 mg/20 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 20 mL, 6 vials of 20 mL
- Marketing authorisation holder
- Hikma Pharmaceuticals
- Manufacturer
- Hikma Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at Controlled Room Temperature, Between 20˚C to 25˚C (68˚F to 77˚F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R07AB01 Doxapram
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 June 1965
- Identifiers
- RxCUI 1047087, 1047511DailyMed set ID b8eb330a-a75b-46cb-b694-5be9327ed2ebNDC 0641-6018Application NDA014879
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 20 mL in 1 vial | 0641-6018-01 | Hikma Pharmaceuticals | 23 June 1965 |
| 6 vial in 1 carton / 20 mL in 1 vial | 0641-6018-06 | Hikma Pharmaceuticals | 23 June 1965 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 June 1965 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Doxapram 400 mg/20 mL injection.
Clinical summary
Doxapram is a respiratory stimulant indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. It is available as injection for intravenous use. MedsAcross supplies Doxapram for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DoxapramFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Dopram prescribing information (Hikma Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Dopram 400 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.